MDxHealth (MDXH) Q2 2026 earnings review
Core Revenue Accelerates, Balance Sheet De-Risked, But Profitability Lags
MDxHealth's Q2 report reveals a company successfully executing a high-stakes pivot. After the forced discontinuation of its Resolve UTI business, the continuing core prostate cancer operations delivered accelerating 16% YoY revenue growth ($27.2M). Crucially, management neatly ring-fenced the $10.4M Medicare recoupment threat by pushing the Delta Lab subsidiary into an Assignment for the Benefit of Creditors (ABC) and shored up the balance sheet with a post-quarter $20M direct placement. However, the top-line success and risk mitigation are overshadowed by a deteriorating bottom line. Driven by ExoDx integration expenses, operating losses surged 236% YoY to $5.1M, and Adjusted EBITDA reversed into negative territory.
🐂 Bull Case
By placing the Delta Lab subsidiary into an ABC process, MDxHealth effectively isolated the $10.4M Medicare recoupment risk from its core operations, removing a major liquidity overhang.
Following Q1's integration distractions, Tissue-based test volumes rebounded 13% sequentially (12,525 tests), confirming management's narrative that the newly focused sales force is regaining traction.
🐻 Bear Case
The ExoDx acquisition has dramatically inflated the cost structure. Operating expenses jumped 31% YoY, causing Adjusted EBITDA to swing from a positive $1.1M in 25Q2 to negative $2.3M in 26Q2.
Gross margin contracted by 290 basis points YoY to 65.7%. The shift in test mix toward liquid biopsy (ExoDx) appears to be diluting the higher margins historically commanded by the tissue portfolio.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for masterfully navigating the Novitas crisis and successfully transitioning the sales force. The top-line growth is real, but until the heavy ExoDx-related operating expenses normalize and EBITDA turns positive again, the financial profile remains stressed.
Key Themes
Tissue Volumes: Distraction Fades, Sequential Growth Resumes
In Q1, tissue-based tests (Confirm mdx and GPS) suffered as the sales force was distracted by the Resolve wind-down and ExoDx cross-training. Q2 shows this was a temporary blip. Tissue volumes jumped 13% sequentially from Q1 (11,110 to 12,525). While still down 1% YoY, the trajectory is clearly accelerating and confirms that the '100% focus on core prostate cancer' strategy is working.
Legal Jiu-Jitsu: The Delta Lab ABC
The $10.4M Novitas recoupment claim for the discontinued Resolve business was a severe threat to MDxHealth's cash runway. By executing an Assignment for the Benefit of Creditors (ABC) for the independently operated Delta Lab subsidiary on August 3, management expedited the orderly disposition of the liability without bleeding the parent company's cash. This aggressive legal maneuver significantly de-risks the overall corporate profile.
ExoDx Integration Costs Crushing Operating Leverage
Management previously promised a path to a 10% Adjusted EBITDA margin exiting 2026. Currently, the trend is reversing. Q2 operating expenses surged 31% YoY to $23.0M, drastically outpacing the 16% revenue growth. This structural cost bloat, driven by the ExoDx acquisition, resulted in a $5.1M operating loss. The company must prove it can digest these costs in the second half of the year.
Liquid Biopsy Volumes Scaling Rapidly
The transition from the legacy Select mdx test to the acquired ExoDx test is yielding massive volume gains. Q2 liquid-based test volume reached 13,578, compared to just 4,455 Select mdx tests in the same period last year. This proves the successful conversion of the customer base and validates the rationale behind the ExoDx acquisition.
Test Mix Diluting Gross Margins
Gross margin decelerated from 68.6% in 25Q2 to 65.7% in 26Q2. Management explicitly attributed this 290 bps reduction to 'test mix'. As the liquid-based ExoDx tests rapidly outgrow the legacy tissue-based tests, the blended gross margin profile of the company is deteriorating. This makes achieving operating profitability even harder.
AI and Oxford PROTECT Study Advancements
Technology and clinical evidence remain core drivers. The company highlighted the peer-reviewed publication of GPS PROMPT results and its ongoing AI initiatives to enhance the endpoints for the massive, long-term PROTECT study. Management believes these specific technology integrations will expand market conversion in the active surveillance population.
Macro: Vulnerability to Medicare Policy Shifts
The entire Resolve UTI business was wiped out by a sudden, unexplained policy posture change from Novitas. While the core prostate business is currently stable under different coverage dynamics, the Novitas saga highlights the fragile macro regulatory environment for diagnostics companies relying heavily on single Medicare administrators.
Other KPIs
Reversing. Down from a positive $1.1 million in the prior year period. Management maintains this will inflect back to positive as they exit 2026, but the current trajectory shows heavy ExoDx-related integration strain.
The company ended Q2 with $19.2M in cash, down from $29M at year-end 2025. However, they aggressively fortified the balance sheet via a $20M registered direct placement on August 11, sold to institutional investors at $0.454 per share. This cash injection provides the necessary runway to reach expected profitability.
Guidance
Stable. The company explicitly stated they are on a 'clear path toward meeting or exceeding' this target. At the midpoint, this represents 23% YoY growth over the 2025 core cancer business, implying that revenue generation will accelerate in H2.
Key Questions
Delta Lab ABC Veil Piercing
With the Delta Lab subsidiary placed into an Assignment for the Benefit of Creditors, how completely is the parent company shielded from the $10.4M Novitas recoupment claim? Is there any risk of Medicare withholding payments from the core prostate cancer business to offset the UTI claims?
ExoDx Margin Profile
Gross margins dropped nearly 300 basis points YoY due to test mix. As ExoDx continues to outpace tissue growth, what is the expected long-term floor for gross margins, and how does this impact the targeted 10% EBITDA margin exit rate?
OpEx Normalization
Operating expenses grew 31% YoY in Q2. When exactly do the integration costs from the ExoDx acquisition begin to roll off, and what is the normalized quarterly OpEx run-rate expected for H2 2026?